2026-10-14T13:35:55Z https://api.figshare.com/v2/oai

oai:figshare.com:article/30729362 2026-09-15T18:25:47Z category_24502 item_type_3 month_year_09_2026

CITE_seq Cenfu Wei (22694909) Gastroenterology and hepatology CITESeq UC VDZ <p dir="ltr">A major barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using daily patient-reported outcomes from a phase 3b comparative trial of 768 participants, we identified four distinct patient response trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor) in UC. Validation in a second phase 3 trial of 591 participants linked vedolizumab trajectories to long-term disease complications. Bulk, single-cell, and spatial, transcriptomics and proteomics, identified vascular inflammation to be associated with vedolizumab nonresponse via SPP1+ monocytes and the angiopoetin-2 pathway. In a real-world cohort of 3,187 patients with UC, concomitant use of renin-angiotensin system inhibitors (modulators of vascular inflammation and angiopoietin-2 signaling) was associated with reduced long-term complications for vedolizumab but not anti-cytokine therapies. These findings define a response trajectory-based taxonomy, and endotype-specific outcome prediction, implicating vascular inflammation as a drug-specific and targetable resistance pathway for vedolizumab in UC.</p> 2026-09-15T18:25:47Z Dataset Dataset 10.6084/m9.figshare.30729362.v1 https://figshare.com/articles/dataset/CITE_seq/30729362 CC BY 4.0